Reshaping the HIV treatment and prevention landscape
Sustainable Growth
Comprehensive new commercial approach to drive growth
Unlock
03
Blenrep LCI
otilimab
pipeline value
Zejula LCI
Jemperli LCI*
IO combos
Maximise priority
02 brands & key markets
Cost base, Policies,
01 Organisation, Capabilities
Culture
Portfolio and organisational transformation
HCPE Healthcare Practitioner Engagement; SFI Sales Force Incentives
*Tesaro asset
daprodustat
gepotidacin
HBV ASO ('836)
Men ABCWY
RSV OA
CAB PrEP
depemokimab ('294)
sotrovimab
gsk
Business
Development
Vaccines:
Specialty Care:
Bexsero
Shingrix
Nucala, Benlysta
Zejula, Blenrep,
Gen. Medicines:
Trelegy
Markets:
US
Growth brands
China
Jemperli*
Dovato,
Cabenuva
Cost Base
Supply chain optimisation
Key policy changes: HCPE, SFI
Leadership & Culture
Portfolio & Footprint optimisation
Specialty Care Capabilities
28View entire presentation